ERYTHROCYTE SEDIMENTATION RATE AND C-REACTIVE PROTEIN AS MARKER OF ACUTE VERSUS CHRONIC MEDICAL CONDITIONS
AbstractBackground: The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are frequently requested investigations that aid health professionals in precisely diagnosing and following a number of complicated disease conditions. The aim of this study is to ascertain whether a rise in any of these acute phase reactants has predilection for an acute illness versus chronic disease. Methods: Current study includes 144 patients admitted to Medical ward and Intensive care unit of Khan Research Laboratory (KRL) Hospital Islamabad from January to April 2017. ESR was measured using conventional Westergren method. CRP level (mg/L) was measured from venous or capillary blood using a point of care testing (POCT) device. SPSS version 20 was used for data analysis. Results: Out of 144 patients who participated in this study 60.5% (n=87) were males while 39.6% (n=57) were females. Mean age was 53.4±18.9 years. Among acute medical conditions, Pneumonia and Enteric fever were common 13.2% (n=12) each. Diabetes Mellitus (DM) with complications was the commonest chronic medical condition 22.6% (n=12). Thirty-two patients had ESR <15 mm/Hour; out of them 71.8% (n=23) had acute while 28.2% (n=9) had chronic medical conditions. Thirty-four patients had ESR ≥15 & <30 mm/Hour; out of them 52.9% (n=18) had acute while 47.1% (n=16) had chronic medical conditions. Seventy-eight patients had ESR ≥30 mm/Hour; out of them 64.1% (n=50) had acute while 35.9% (n=28) had chronic medical conditions. All results were statistically significant with p-value ≤0.05. 75 patients had CRP <10 mg/L; out of them 66.7% (n=50) had acute while 33.3% (n=25) had chronic medical conditions. Sixty-nine patients had CRP ≥10 & <100 mg/L; out of them 59.4% (n=41) had acute while 40.6% (n=28) had chronic medical conditions. All results were statistically significant with p-value ≤0.05. In acute medical conditions mean CRP was 16.8±17.7 mg/L and average ESR was 35.9±25.6 mm/Hour. In chronic medical conditions mean CRP was 16.3±17.2 mg/L and mean ESR was 40.8±32.5 mm/Hour. Conclusion: No difference was found between CRP and ESR as markers of acute versus chronic medical conditions. Both CRP and ESR have positive association with acute as well as chronic medical conditions. Elevated ESR was seen more frequently in acute medical conditions as compared to CRP. Keywords: Erythrocyte sedimentation rate; ESR; C-reactive protein; CRP; Acute medical conditions; Chronic medical conditions; Pneumonia; Typhoid; Diabetes Mellitus; Pakistan
Ahmed MS, Jadhav AB, Hassan A, Meng QH. Acute Phase Reactants as Novel Predictors of Cardiovascular Disease. ISRN Inflamm 2012;2012:953461.
Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ 2016;115(6):317–21.
Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52(4):561–71.
Kushner I, Samols D. Oswald Avery and the pneumococcus. Pharos Alpha Omega Alpha Honor Med Soc 2011;74(2):14–8.
Litao MK, Kamat D. Erythrocyte sedimentation rate and C-reactive protein: how best to use them in clinical practice. Pediatr Ann 2014;43(10):417–420.
Markanday A. Acute Phase Reactants in Infections: Evidence-Based review and a guide for clinicians. Open Forum Infect Dis 2015;2(3):ofv098.
Bedell SE, Bush BT. Erythrocyte sedimentation rate. From folklore to facts. Am J Med 1985;78(6 Pt 1):1001–9.
Batlivala SP. Focus on diagnosis: the erythrocyte sedimentation rate and the C-reactive protein test. Pediatr Rev 2009;30(2):72–4.
Olshaker JS, Jerrard DA. The erythrocyte sedimentation rate. J Emerg Med 1997;15(6):869–74.
Ahmed YF, Abbag FI, Al-Qahtani JM, Ghazali BM, Abolfotouh MA. Erythrocyte sedimentation rate during steady state, painful crisis and infection in children with sickle cell disease. Saudi Med J 2000;21(5):461–3.
Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 1999;60(5):1443–50.
Amerio P, Girardelli CR, Proietto G, Forleo P, Cerritelli L, Feliciani C, et al. Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 2002;12(2):165–9.
Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982;9(2):224–8.
Sbong S, Feldman M. Frequency and causes of C-reactive protein and erythrocyte sedimentation rate disagreements in adults. Int J Rheum Dis 2015;18(1):29–32.
Kushner I. C-reactive protein in rheumatology. Arthritis Rheum 1991;34(8):1065–8.
Nestel AR. ESR changes with age--a forgotten pearl. BMJ 2012;344:e1403–9.
Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed) 1983;286(6361):266.
Leff RD, Akre SP. Obesity and the erythrocyte sedimentation rate. Ann Intern Med 1986;105(1):143.
Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol 2009;36(8):1606–10.
Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS. Kelly’s Textbook of Rheumatology. 8th ed. Philadelphia: Saunders Elsevier; 2009.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448–54.
Levine MJ, McGuire KJ, McGowan KL, Flynn JM. Assessment of the test characteristics of C-reactive protein for septic arthritis in children. J Pediatr Orthop 2003;23(3):373–7.
Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis 2011;5(1):61–78.
Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82(5):346–53.
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94(3):311–21.
WHO. Global Tuberculosis Control: World Health Organization report 2011.
Le Gall C, Désidéri-Vaillant C, Nicolas X. [Significations of extremely elevated C-reactive protein: about 91 cases in a French hospital center]. Pathol Biol (Paris) 2011;59(6):319–20.
Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005;117(2):104–11.
Fincher RM, Page MI. Clinical significance of extreme elevation of the erythrocyte sedimentation rate. Arch Intern Med 1986;146(8):1581–3.
Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008;59(12):1814–20.
Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014;16(1):R40.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13(5):426–35.
Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2012;64(9):3034–42.